PRO/AH/EDR> COVID-19 update (504): vaccine efficacy, Africa, WHO, global

COVID-19 — Worldwide/Unknown
“NIAID and Okairos (a company later acquired by GSK) developed an Ebola vaccine candidate (now licensed to the Sabin Vaccine Institute) that uses a chimpanzee adenovirus (cAd3) vector, or carrier, to deliver Ebola genetic material. The gene inserts express an Ebola virus protein designed to prompt the human body to make an immune response.
“The cAd3-EBO Z vaccine (designed to protect against the Ebola Zaire virus species) proved to be safe and immunogenic when evaluated in numerous Phase 1